Edition:
United States

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

9.62USD
2:06pm EDT
Change (% chg)

$0.21 (+2.23%)
Prev Close
$9.41
Open
$9.42
Day's High
$9.74
Day's Low
$9.38
Volume
80,945
Avg. Vol
147,182
52-wk High
$20.25
52-wk Low
$9.04

Chart for

About

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in... (more)

Overall

Beta: 1.08
Market Cap(Mil.): $525.21
Shares Outstanding(Mil.): 56.11
Dividend: --
Yield (%): --

Financials

  AKBA.OQ Industry Sector
P/E (TTM): -- 173.69 32.21
EPS (TTM): -1.91 -- --
ROI: -37.90 -0.70 13.05
ROE: -82.06 -2.69 14.90

BRIEF-Akebia Therapeutics Announces Proposed Public Offering Of Common Stock

* AKEBIA THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Mar 22 2018

BRIEF-Akebia Therapeutics Inc Files For Potential Mixed Shelf Offering Amount Not Disclosed - SEC Filing

* AKEBIA THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; AMOUNT NOT DISCLOSED - SEC FILING Source text (http://bit.ly/2tG5aJJ) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 12 2018

BRIEF-Akebia Therapeutics Announces Q4 Earnings Per Share $0.25

* AKEBIA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Mar 12 2018

BRIEF-Akebia Therapeutics Gives Update On Vadadustat Development Program

* AKEBIA THERAPEUTICS PROVIDES UPDATE ON VADADUSTAT DEVELOPMENT PROGRAM

Feb 12 2018

BRIEF-Akebia Therapeutics reports Q3 loss per share $0.49

* Akebia Therapeutics announces third quarter 2017 financial results

Nov 08 2017

BRIEF-Invirsa secures seed financing to develop new approach

* Invirsa secures seed financing to develop new approach to treating common infectious diseases that affect millions annually Source text for Eikon: Further company coverage:

Nov 07 2017

Competitors

  Price Chg
Amgen, Inc. (AMGN.OQ) $175.23 +0.40
Johnson & Johnson (JNJ.N) $128.80 +2.04
Roche Holding Ltd. (ROG.S) CHF218.10 +0.35
Roche Holding Ltd. (RO.S) CHF223.00 +0.40
FibroGen Inc (FGEN.OQ) $47.35 +0.70
AstraZeneca plc (AZN.L) 4,992.00 +1.00
Astellas Pharma Inc (4503.T) ¥1,544 -34.00
GlaxoSmithKline plc (GSK.L) 1,436.80 +24.60
Bayer AG (BAYGn.DE) €97.34 -0.13
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates